TG Therapeutics, Inc. (TGTX) stock
TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$62.71−0.05 (-0.08%)
Close on Nov 17, 2026Market cap $9.60BP/E 22.9Yield –
TG Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
TG Therapeutics's enterprise value was $10.20B on Nov 11, 2026, against $5.23B a year earlier. Over the last 5 years it ranged from $400.85M to $10.20B, with a median of $3.52B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $10.20B | +117.3% |
| 2025 | Dec 31, 2025 | $4.69B | +2.2% |
| 2024 | Dec 31, 2024 | $4.59B | +86.9% |
| 2023 | Dec 29, 2023 | $2.46B | +54.2% |
| 2022 | Dec 30, 2022 | $1.59B | -32.2% |
| 2021 | Dec 31, 2021 | $2.35B | -63.7% |
| 2020 | Dec 31, 2020 | $6.48B | +530.0% |
| 2019 | Dec 31, 2019 | $1.03B | +324.7% |
| 2018 | Dec 31, 2018 | $242.28M | -50.3% |
| 2017 | Dec 29, 2017 | $487.55M | +151.6% |
| 2016 | Dec 30, 2016 | $193.77M | -62.1% |
| 2015 | Dec 31, 2015 | $511.13M | -13.2% |
| 2014 | Dec 31, 2014 | $589.12M | +615.4% |
| 2013 | Dec 31, 2013 | $82.35M | +40.7% |
| 2012 | Dec 31, 2012 | $58.51M | +253.8% |
| 2011 | Dec 30, 2011 | $16.54M | – |
See a number that looks wrong?